Join Growin Stock Community!

Oculis holding agOCS.US Overview

US StockHealthcare
(No presentation for OCS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OCS AI Insights

OCS Overall Performance

OCS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OCS Recent Performance

-4.45%

Oculis holding ag

0.05%

Avg of Sector

-0.31%

S&P500

OCS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OCS Key Information

OCS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OCS Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Price of OCS

OCS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OCS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.82
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2149.31
PB Ratio
10.02
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-36145.14%
Revenue Growth (YoY)
-66.82%
Profit Growth (YoY)
-66.82%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.82
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2149.31
PB Ratio
10.02
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-36145.14%
Revenue Growth (YoY)
-66.82%
Profit Growth (YoY)
-66.82%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is OCS's latest earnings report released?

    The most recent financial report for Oculis holding ag (OCS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OCS's short-term business performance and financial health. For the latest updates on OCS's earnings releases, visit this page regularly.

  • How is OCS's revenue growth?

    In the latest financial report, Oculis holding ag (OCS) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does OCS have?

    As of the end of the reporting period, Oculis holding ag (OCS) had total debt of 2.47M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does OCS have?

    At the end of the period, Oculis holding ag (OCS) held Total Cash and Cash Equivalents of 46.44M, accounting for 0.28 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is OCS's EPS continuing to grow?

    According to the past four quarterly reports, Oculis holding ag (OCS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OCS?

    Oculis holding ag (OCS)'s Free Cash Flow (FCF) for the period is -13.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 27.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.